Τετάρτη 1 Νοεμβρίου 2017

First-Line Abemaciclib Effective in ER+ Breast Cancer [News in Brief]

Interim data from the MONARCH3 study indicate that abemaciclib is an effective first-line therapy for advanced ER-positive, HER2-negative breast cancer. Adding the investigational CDK4/6 inhibitor to letrozole significantly improved patients' progression-free survival, compared with those given a placebo alongside endocrine therapy.



http://ift.tt/2iTSMRs

Δεν υπάρχουν σχόλια:

Δημοσίευση σχολίου